Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo has received Japanese manufacturing and marketing approval for Memary 5mg, 10mg and 20mg tablets (generic name: Memantine Hydrochloride) to treat moderate to severe Alzheimer's Disease (AD).
Subscribe to our email newsletter
Developed by Merz Pharmaceuticals, Memary is an N-methyl-D-aspartate (NMDA) receptor antagonist which has been approved by European EMEA in 2002 and by the US Food and Drug Administration in 2003.
The AD drug is currently marketed in 70 countries throughout the world.